Silence Therapeutics Pointing To 300p

One of the simplest and more effective charting rules is that when a stock or market is below the 200 day moving average we can regard it as being bearish, and a sell into strength, whereas above the 200 day line the Bulls are regarded as being in a position of dominance.

This is essentially what we are seeing in terms of Silence Therapeutics PLC (LON:SLN) on the daily chart over the near-term, but with the transition from bearish to bullish somewhat blurred in terms of an extended January/February break above the key trend determining chart feature.

 

 

SLN Silence Therapeutics Technical Analysis 130315

 

But at least it can be seen how overall since the middle of October when there was a selling climax towards £1.60, we have been treated to a reasonable progression to the upside within a rising trend channel from the autumn. The floor of the channel currently runs at £2.30 which is level with the 50 day moving average, and this is regarded as the near-term stop loss for those close to the market on this stock.

Otherwise the message is that while there is no end of day close back below the 200 day moving average of 217p, especially while the RSI now at 53 remains above neutral 50, we can look to Silence Therapeutics heating the October rising trend channel top at 300p as soon as the end of April.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    X
    LinkedIn
    DirectorsTalk

    More articles like this

    Silence Therapeutics plc

    Silence Therapeutics analyst presentation 6th March

    Silence Therapeutics plc, (LON:SLN) a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, will announce its Preliminary Results for the twelve months ended

    Silence Therapeutics plc

    A further European patent for Silence Therapeutics plc

    Silence Therapeutics plc, AIM:SLN a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announced today that on 17 January 2018 the European Patent

    Silence Therapeutics plc

    Silence Therapeutics Notice of Interim Results

    Silence Therapeutics plc, LON:SLN (“Silence” or “the Company”) a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, will announce results for the six